Morocco bets on video game industry to provide jobs and diversify economy
State officials invited developers, students and tech companies from around the world to a gaming expo in Rabat this week, where guests tested new games, competed in e-sports tournaments and heard about new initiatives to bring the burgeoning industry to Morocco. Attendees at the Morocco Gaming Expo battled through shooting games, explored immersive virtual reality worlds, tested educational platforms and mingled with mobile providers eager to stake their claim in the growing mobile gaming market.
The event, in its second year, is one of the few ways in which African countries are diversifying their economies and attracting new industries for their young workforces.
Morocco is positioning itself as one of Africa's first countries to roll out targeted strategies for the gaming industry. Mehdi Ben Said, Morocco's Minister of Youth, Culture and Communication, said the government aims to both attract international game companies to Morocco and incentivize Moroccan developers to create their own products. With youth unemployment close to 30% and many young people eyeing opportunities abroad, the gaming industry could be a way to spark job growth and diversify opportunities, he said.
'The objective is not only to generate revenue, but also to empower youth,' Ben Said said. 'We must offer real alternatives to our young people by opening up new career opportunities.'
With more than $200 billion in annual revenue and 3 billion players, the global market for video games is undergoing rapid growth. But even as smartphones have become ubiquitous in the Middle East and Africa, the industry has remained concentrated in East Asia, North America and Western Europe. Driven primarily by game sales, Morocco's industry currently generates over $500 million annually, according to state officials, who aim to double this revenue by 2030.
Morocco is launching training programs in game design, programming and virtual reality alongside an industrial park where startups can incubate new games. The initiative includes a $26-million investment to open 'Rabat Gaming City,' featuring training, co-working spaces and full-scale production studios.
For students the industry offers a chance to turn a passion into a career, said Fadwa Bezzazi, coordinator of Universite Mohammed V's undergraduate club in computer science and virtual reality. Students, who are already spending money on mobile or PC games, want to find ways to put what they're learning in the classroom into practice.
'I'm not going to say we're preparing them for the future, because that future is already here,' she said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
22 minutes ago
- Bloomberg
JPMorgan, Goldman Sachs See More Upside for South African Stocks
By South African stocks are poised to extend their rally in the second half, buoyed by an improving outlook for the domestic economy and supportive monetary policy, according to JPMorgan Chase & Co. The FTSE/JSE Africa All Share Index is up 23% this year in dollar terms, outperforming both the MSCI Emerging Markets Index and the S&P 500. JPMorgan expects the momentum to continue led by South Africa Inc. shares as they stand to benefit from local economic tailwinds.
Yahoo
26 minutes ago
- Yahoo
PenFed Foundation for Military Heroes Awards $50,000 Grant to Soldiers to Sidelines to Empower Military Community as Coaches
Soldiers to Sidelines is dedicated to educating, certifying, developing and supporting members of the military community to become expert coaches and exemplary role models for youth TYSONS Va., July 7, 2025 /PRNewswire/ -- The PenFed Foundation for Military Heroes today announced that it has awarded Soldiers to Sidelines a $50,000 Military Heroes Grant to support their Coaching Summit, scheduled for July 24-26th in Nashville, Tenn. This grant will directly support 450 individuals. Soldiers to Sidelines is dedicated to educating, certifying, developing and supporting members of the military community to become expert coaches and exemplary role models for today's impressionable youth. "It's a privilege to come alongside Soldiers to Sidelines in their mission of cultivating community connection through athletics," said PenFed Foundation for Military Heroes President Andrea McCarren. "We are honored to join and support their impactful work with youth and military communities." Soldiers to Sidelines empowers and supports members of the military community through a comprehensive program. To help veterans, service members, military spouses and Gold Star families fulfill their passion for service and desire for purposeful work, Soldier Coaches are equipped with high human skills and coaching knowledge, along with connections to the athletic community. Following the belief that our veterans and service members can have a meaningful and lasting impact on others through athletics, this is all made possible by a comprehensive training and support network of top sports, military, business professionals and donors. "The Coaching Summit is at the heart of our pursuit to equip those in the military community to positively influence youth and help them become the leaders of the future," said Soldiers to Sidelines Founder & Executive Director Harrison Bernstein. "We are incredibly appreciative of the PenFed Foundation for Military Heroes' support in making this Summit and its future impact possible." About PenFed Foundation for Military Heroes Founded in 2001, The PenFed Foundation for Military Heroes is a national nonprofit organization that supports veterans in their transition from service to success in the civilian world. Affiliated with PenFed Credit Union, the Foundation has provided more than $55 million in financial support to veterans, active-duty service members and military families. PenFed Credit Union covers most of the salaries and administrative costs of The PenFed Foundation for Military Heroes, so more of your donation goes right to our programs. To learn more, please visit View original content to download multimedia: SOURCE PenFed Foundation for Military Heroes Sign in to access your portfolio
Associated Press
an hour ago
- Associated Press
NanoViricides (NNVC) Accelerates MPox Drug Development, Citing Strong Business and Public Health Case
NanoViricides, Inc. (NYSE Amer.: NNVC), a clinical-stage biopharmaceutical company and a pioneer in broad-spectrum antivirals, announced today its accelerated plans to advance its lead drug candidate, NV-387, into Phase II clinical trials for MPox. This strategic decision positions the company to potentially bring a much-needed antiviral to market faster, addressing a critical global health need while also paving the way for further pipeline development. NanoViricides highlighted several key reasons for prioritizing MPox as the first indication for NV-387's Phase II development, even with strong efficacy data in animal studies for other major viral threats like RSV, Influenza, and COVID. Strategic Advantages of the MPox Focus The company believes its focus on MPox offers significant advantages: Urgent Need and Timely Trial Completion: With a continuing MPox epidemic in the African Region, there's a pressing demand for effective treatments. This also facilitates patient recruitment, enabling a more rapid completion of the clinical trial. Cost-Effectiveness: Conducting clinical trials in the African Region is substantially more economical compared to the US or Europe, allowing NanoViricides to optimize its research budget. Validation of Animal Model Data: A successful Phase II trial for MPox in humans would validate the company's use of lethal challenge animal models. This is a critical point, as NanoViricides' animal studies have consistently shown NV-387 to be significantly superior to existing drugs across all tested infections. Strong Financial and Public Health Case: The recent failure of tecovirimat (Tpoxx) in MPox clinical trials creates a clear void in the US Strategic National Stockpile (SNS) for effective antivirals against orthopoxviruses like MPox and Smallpox. Both tecovirimat and brincidofovir (Tembexa), currently approved for Smallpox under the 'FDA Animal Rule,' have shown limitations. Brincidofovir failed due to liver toxicity, and tecovirimat demonstrated no superiority over standard care. NanoViricides believes NV-387 could become a crucial addition to the SNS, potentially securing substantial initial acquisition contracts. Addressing a Critical Vulnerability: Unlike small chemical drugs that viruses can readily escape through mutations, NanoViricides' host-mimetic nanomedicine technology is designed to make it difficult for viruses to develop resistance. This is particularly important for bioterrorism readiness, as manipulated forms of viruses like Smallpox could be engineered to resist conventional treatments. The company emphasizes the strong case for the US Department of Health and Human Services (HHS) to support NV-387 development for bioterrorism preparedness. Innovative Drug Delivery Adding to its strategic advantages, NV-387 will be administered as 'NV-387 Oral Gummies.' This soft solid formulation is designed to dissolve naturally in the oral cavity, eliminating the need for swallowing pills or capsules. This is a significant benefit for MPox patients who often suffer from painful oral lesions, making swallowing difficult. Addressing the Broader MPox Threat The ongoing MPox epidemic in the Democratic Republic of Congo (DRC) is driven by Clade 1a and the more transmissible Clade 1b subtypes, which have higher case fatality rates than the Clade 2b circulating in the Western world. While sporadic Clade 1 cases have been reported in the USA without further spread, the potential for a larger epidemic cannot be ignored. NanoViricides asserts that readiness with an effective drug against Clade 1 MPox is crucial for national health security. NanoViricides, Inc. is a publicly traded clinical-stage company focused on creating special purpose nanomaterials for antiviral therapy. The company's innovative nanoviricide™ class of drug candidates is based on technology and proprietary know-how from TheraCour Pharma, Inc. Other notable stocks to keep on top of radar include Summit Therapeutics (SMMT), Regulus Therapeutics (RGLS), Vigil Neuroscience (VIGL), Alaunos Therapeutics (TCRT), CervoMed Inc. (CRVO), Niagen Bioscience (NAGE) and Beam Therapeutics (BEAM). Source: Disclaimer: This blog post is for informational purposes only and does not constitute financial advice or an endorsement of BURU or its strategies. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at has been compensated fifteen hundred dollars by a 3rd party EDM Media Consulting Group for content distribution services on nnvc or July 6th, 2025. is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like 'believes,' 'anticipates,' 'estimates,' 'expects,' 'projects,' 'intends,' or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at It is always important to conduct thorough due diligence and exercise caution in is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. is not a fiduciary by virtue of any person's use of or access to this content. This article is for informational purposes only and does not constitute investment advice. Always conduct your own research before making investment decisions. This analysis represents the opinion of the author based on publicly available information and should not be considered investment advice. Investors should conduct their own due diligence before making investment decisions. Media Contact Company Name: UsaStockReport Contact Person: Ash K Email: [email protected] City: Frisco State: Texas Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: NanoViricides (NNVC) Accelerates MPox Drug Development, Citing Strong Business and Public Health Case
